arbidol
arb
russianmad
small
indolederiv
molecul
licens
russia
china
prophylaxi
treatment
influenza
respiratori
viral
infect
also
demonstr
inhibitori
activ
virus
envelop
respons
emerg
global
preval
infecti
diseas
hepat
b
c
gastroenter
hemorrhag
fever
enceph
review
explor
possibl
pertin
arb
broadspectrum
antivir
care
examin
physicochem
properti
pharmacokinet
toxic
molecular
mechan
action
recent
studi
suggest
arb
dual
interact
membran
aromat
amino
acid
protein
may
central
broadspectrum
antivir
activ
could
impact
viru
andor
cellular
function
critic
step
viruscel
interact
therebi
posit
arb
directact
antivir
daa
hosttarget
agent
hta
context
recent
studi
anim
human
discuss
prospect
clinic
use
arb
variou
viral
infect
arbidol
arb
administ
decad
russia
china
influenza
major
advers
effect
report
vast
potenti
broadspectrum
antivir
agent
defin
vitro
vivo
studi
lend
hope
clinic
use
variou
infecti
diseas
present
therapeut
control
howev
evid
benefici
effect
human
especi
perspect
longterm
administr
chronic
diseas
remain
equivoc
could
attribut
rel
lack
standard
anim
studi
control
clinic
trial
healthi
infect
subject
addit
influenza
pathogen
human
respiratori
virus
arb
show
mainli
vitro
inhibitori
activ
hepat
b
viru
hbv
hepat
c
viru
hcv
chikungunya
viru
chikv
reoviru
hantaan
viru
coxsacki
viru
paper
updat
current
knowledg
arb
link
physicochem
properti
molecular
mode
action
toxic
possibl
pharmaceut
form
outlin
recent
studi
molecular
cellular
mechan
arb
may
inhibit
sever
step
viral
life
cycl
discuss
arb
emerg
directact
agent
daa
hosttarget
agent
hta
china
toxic
arb
dimethylamino
methyl
phenylthio
methyl
hydrochlorid
monohydr
small
indol
deriv
fig
also
call
umifenovir
invent
attribut
joint
consortium
russian
scientist
chemicalpharmaceut
scientif
research
institut
russia
scientif
research
institut
medic
radiolog
obninsk
leningradpasteur
scientif
research
institut
epidemiolog
microbiolog
year
ago
describ
arbidolnetrobertnikolaevichglushkovhtml
discoverypdf
one
first
descript
chemic
synthesi
publish
trofimov
et
al
modifi
later
miller
bergeron
drug
manufactur
moscowbas
subsidiari
pharmstandard
group
see
shijiazhuang
china
http
wwwsjzsiyaocomproductsdetail
arb
market
year
russia
use
sinc
china
prophylaxi
treatment
human
pulmonari
diseas
caus
influenza
b
virus
human
pathogen
respiratori
virus
review
boriskin
et
al
brook
et
al
also
use
prevent
flu
epidem
poultri
china
berendsen
et
al
avail
chines
compani
special
anim
health
product
http
first
report
clinic
efficaci
arb
publish
russian
group
student
industri
worker
epidem
influenza
outbreak
acut
respiratori
diseas
gagarinova
et
al
obrosovaserova
et
al
later
studi
perform
servicemen
report
efficaci
costeffect
prophylact
cur
treatment
arb
acut
respiratori
viral
infect
arb
shown
decreas
febril
period
shumilov
et
al
shuster
et
al
inform
avail
durat
arb
treatment
vari
day
chines
clinic
studi
similar
design
patient
inclus
criteria
arb
dose
durat
administr
point
compar
efficaci
toler
arb
wang
et
al
arb
efficaci
compar
well
even
better
commonli
use
antivir
molecul
rimantadin
roflual
oseltamivir
tamiflu
ribavirin
interferonalpha
kolobukhina
et
al
kolobukhina
et
al
leneva
shuster
potenti
vitro
effect
rimantadin
influenza
b
virus
enhanc
immunomodulatori
properti
antiflu
vaccin
vaxigrip
administ
cohort
elderli
patient
semenenko
et
al
benefici
effect
flu
patient
anoth
infecti
immunodefici
glushkov
et
al
studi
point
dual
pharmacolog
action
arb
specif
effect
respiratori
virus
immunestimul
effect
induct
serum
interferon
activ
phagocyt
studi
also
conduct
children
suffer
flu
acut
viral
respiratori
diseas
beliaev
et
al
drinevskii
et
al
latter
studi
document
one
conduct
children
year
old
infect
influenza
b
respiratori
virus
treatment
arb
effici
reduc
durat
infect
occurr
complic
immunomodul
action
suggest
compani
current
market
arb
sponsor
vast
clinic
trial
conduct
children
year
old
arb
given
either
prophylaxi
twice
week
week
daili
day
ii
treatment
thrice
daili
day
case
arb
treatment
led
signific
reduct
durat
clinic
sign
observ
advers
effect
complic
see
http
arbidolorgarbidolchildrensstudypdf
interestingli
studi
compar
antivir
viral
strain
sensit
arb
wherea
sever
resist
variant
found
rimantadin
cf
also
recent
iatsyshina
et
al
lvov
et
al
see
also
section
sinc
arb
also
patent
medicin
use
antivir
agent
atyp
pneumonia
induc
sever
acut
respiratori
syndrom
coronaviru
sarscov
see
http
recent
doubleblind
random
placebocontrol
phase
iv
clinic
trial
launch
assess
whether
arb
effect
treatment
prophylaxi
flu
common
cold
http
termarbidol
two
dosag
evalu
mgday
day
mgday
day
complet
studi
expect
apart
recent
trial
spite
abund
studi
overal
languag
barrier
render
difficult
precis
evalu
number
subject
enrol
per
studi
way
clinic
trial
design
subsequ
statist
analys
perform
moreov
offici
russian
site
exist
arbidol
arbidolru
inform
could
collect
english
translat
avail
studi
specif
address
arb
toxic
issu
initi
literatur
mostli
russian
avail
acut
toxic
data
report
oral
mgkg
mice
mgkg
rat
guinea
pig
http
glushkov
valu
also
report
elsewher
http
http
arbidolorgrathtml
loginova
et
al
shi
et
al
administ
intraven
arb
exhibit
ld
mgkg
mice
mgkg
rat
eropkin
et
al
longterm
per
os
administr
arb
rat
guinea
pig
rabbit
dog
month
dose
rang
mg
kg
patholog
chang
observ
anim
dose
would
roughli
correspond
therapeut
dose
human
arb
also
report
induc
embryo
toxic
pregnant
femal
rat
alter
reproduct
function
anim
dayadministr
period
mgkg
dose
http
arbidolorgrathtml
recent
data
chines
group
show
good
toler
arb
administ
rat
per
os
daili
dose
rang
mgkg
period
wang
et
al
fact
studi
assess
toxic
combin
arb
acetaminophen
render
difficult
precis
evalu
toxic
molecul
individu
healthi
male
volunt
receiv
singl
mgdose
arb
excel
toler
report
data
appear
arb
welltoler
molecul
high
therapeut
index
administ
period
rang
day
month
date
howev
studi
address
longterm
administr
arb
exampl
context
chronic
infect
indol
deriv
arb
expect
poorli
solubl
aqueou
media
major
repercuss
bioavail
form
administr
pharmacokinet
effort
improv
arb
water
solubl
undertaken
chemic
graft
acrylamid
polym
arb
molecul
eropkin
et
al
antivir
properti
complex
maintain
compar
parent
molecul
also
display
better
vitro
pharmacolog
index
arb
defin
ic
vic
vic
virusinhibit
concentr
howev
polym
develop
arb
solubl
hot
glycerol
remain
solubl
dilut
aqueou
media
administ
vitro
vivo
brook
et
al
howev
pharmacokinet
metabolit
studi
perform
mode
administr
select
sensit
accur
method
detect
arb
human
plasma
highpressur
liquid
chromatographi
design
allow
conclud
interfer
exist
arb
expect
metabolit
metz
et
al
studi
base
upon
hplc
method
evalu
pharmacokinet
paramet
arb
oral
intraven
administr
rat
compar
plasma
elimin
halfliv
maximum
concentr
c
max
obtain
oral
dose
six
time
higher
inject
howev
perform
small
number
anim
liu
et
al
drug
manufactur
russia
china
tablet
capsul
contain
arb
activ
ingredi
initi
russian
studi
human
reveal
main
site
arb
metabol
liver
arb
rapidli
distribut
tissu
organ
maxim
accumul
liver
ww
pituitari
gland
kidney
lymphat
node
thyroid
adren
gland
bone
marrow
lung
plasma
thymu
spleen
less
glushkov
see
http
wwwchemeuropecomenencyclopediaarbidolhtml
plasma
c
max
reach
within
h
h
mgor
mgdose
respect
h
total
intak
dose
arb
excret
unchang
within
h
via
fece
recent
studi
report
much
shorter
plasma
c
max
chines
healthi
volunt
conclud
russian
chines
popul
differ
arb
elimin
rate
liu
et
al
howev
dose
administ
differ
technolog
improv
especi
detect
sensit
might
also
explain
discrep
singl
dose
mg
arb
administ
healthi
volunt
dispers
tablet
capsul
found
bioequival
well
toler
pharmacokinet
oral
singl
vs
multipl
dose
arb
compar
healthi
subject
plasma
sampl
analyz
hplc
metz
et
al
sun
et
al
c
max
increas
linearli
intak
dose
singl
dose
administr
peak
lgml
mgdose
sun
et
al
arb
exhibit
littl
accumul
repeat
dose
pharmacokinet
profil
differ
observ
singl
dosag
base
arb
chemic
structur
sever
metabolit
predict
fig
oxid
sulfur
atom
loss
dimethylamino
methyl
group
ndemethyl
conjug
moieti
pioneer
studi
rat
urin
format
sulfon
sulfoxid
form
confirm
hplc
oral
administr
arbstarch
suspens
anisimova
et
al
glucuronid
sulfat
conjug
also
observ
posit
demethyl
dimethylamino
methyl
group
see
also
liu
et
al
human
urin
administr
singl
mgdose
arb
healthi
subject
metabolit
could
identifi
major
one
arb
glucuronid
sulfoxidearb
sulfinylarb
fig
glucuronid
wang
et
al
similar
metabolit
identifi
rat
observ
arb
could
also
glucuronid
vitro
use
purifi
human
liver
microsom
studi
also
reveal
microsom
recombin
udpglucuronosyltransferas
ugt
major
ugt
isoform
involv
arb
glucuronid
song
et
al
convers
arb
found
inhibit
ibid
liu
et
al
sinc
involv
metabol
sever
drug
eg
acetominophen
diclofenac
potenti
drugdrug
interact
could
lead
advers
effect
care
examin
arb
administ
molecul
complet
pictur
could
obtain
studi
healthi
volunt
receiv
singl
oral
dose
mg
arb
urin
fece
plasma
metabolit
analyz
deng
et
al
metabolit
sulfoxid
dimethylamin
ndemethyl
glucuronideor
sulfateconjug
total
intak
dose
arb
excret
unchang
via
fece
previous
report
boriskin
et
al
sulfinylarb
fig
major
circul
compon
detect
plasma
follow
unmetabol
arb
ndemethylsulfinylarb
sulfonylarb
fig
urin
sampl
contain
mainli
glucuronid
sulfat
conjug
vitro
experi
use
human
liver
intestin
kidney
microsom
recombin
enzym
show
arb
metabol
human
microsom
liver
intestin
kidney
organ
identifi
key
metabol
enzym
arb
still
question
remain
pharmacokinet
properti
arb
metabolit
potenti
antivir
activ
follow
paramet
report
deng
et
al
tmax
arb
dimethylamin
ndemethyl
arb
compar
h
respect
much
longer
sulfinyland
sulfonylarb
h
plasma
elimin
halfliv
metabolit
longer
arb
h
ndemethyl
sulfinyl
sulfonylarb
arb
respect
exposur
metabolit
therefor
greater
arb
main
metabolit
sulfinylarb
expect
accumul
repeat
arb
dose
along
line
sulfinylarb
report
contribut
pharmacolog
activ
associ
arb
sulfonylarb
could
inhibit
protein
kinas
c
lm
demin
et
al
therefor
potenc
durat
effect
agent
may
underestim
measur
arb
concentr
also
predict
base
upon
vitro
data
microsom
vivo
metabolit
could
occur
cell
cultur
especi
studi
address
antivir
effect
arb
hepatotrop
virus
use
liverderiv
cell
line
could
explain
arb
demonstr
greater
efficaci
preincub
condit
metabolit
could
alreadi
produc
exert
specif
effect
see
section
howev
recent
studi
directli
address
vitro
antivir
properti
sulfinyland
sulfonylarb
chikungunya
alphaviru
show
moder
weak
activ
compar
parent
molecul
delogu
et
al
reinforc
observ
preincub
cell
arb
prior
infect
improv
antivir
effect
point
minor
role
arb
metabolit
chikungunya
infect
least
vitro
case
investig
necessari
understand
import
metabolit
efficaci
safeti
arb
due
high
plasma
exposur
long
elimin
halfliv
ii
assess
stabil
circul
tissu
bind
storag
properti
arb
shown
display
antivir
vitro
andor
vivo
activ
number
envelop
nonenvelop
rna
dna
virus
includ
influenza
virus
b
c
respiratori
syncyti
viru
sarscov
adenoviru
parainfluenza
type
polioviru
rhinoviru
coxsackieviru
hantaan
viru
chikungunya
viru
hbv
hcv
review
boriskin
et
al
brook
et
al
brook
et
al
liu
et
al
see
also
tabl
numer
report
russian
describ
antivir
potenc
arb
human
avian
influenza
virus
notabl
highli
pathogen
leneva
shuster
pandem
subtyp
fediakina
et
al
vitro
studi
report
lm
rang
state
effect
arb
compar
ribavirin
superior
rimantadin
rimantadineresist
strain
sensit
arb
romanovskaia
et
al
leneva
et
al
fediakina
et
al
studi
state
potenti
effect
arb
rimantadin
amantadin
influenza
b
virus
burtseva
et
al
howev
adamantan
antivir
scarc
use
influenza
virus
due
low
barrier
resist
studi
access
inform
allow
evalu
stage
viral
life
cycl
target
arb
mode
action
shi
cowork
show
greater
inhibitori
effect
influenza
arb
ad
infect
preincub
viru
shi
et
al
suggest
membran
impregn
andor
metabolit
could
underli
arb
antivir
activ
see
section
arb
demonstr
similar
vitro
antivir
activ
refer
drug
ribavirin
virazol
respiratori
syncyti
viru
rsv
envelop
viru
paramyxovirida
famili
leneva
et
al
arb
effici
ad
infect
shi
et
al
lm
recent
tannock
cowork
report
potent
antivir
activ
arb
sever
viru
famili
respons
respiratori
infect
anim
human
particular
influenza
lm
nonenvelop
picornavirida
polioviru
rhinoviru
brook
et
al
see
also
brook
et
al
concern
rsv
reduct
plaqu
size
number
could
observ
hamper
estim
studi
arb
ad
cell
aqueou
glycerol
solut
instead
classic
dilut
dmso
studi
leneva
et
al
shi
et
al
might
explain
discrep
antivir
effect
rsv
arb
also
display
inhibitori
effect
coxsackieviru
anoth
member
picornavirida
famili
respons
varieti
patholog
includ
respiratori
infect
myocard
enceph
arb
activ
viru
virucid
test
ad
infect
inhibit
late
stage
viral
replic
inde
shown
prevent
viral
rna
synthesi
dosedepend
manner
maxim
effect
obtain
lm
one
studi
russian
describ
vitro
antivir
activ
arb
sarscov
ad
viral
infect
high
concentr
lm
khamitov
et
al
depend
cell
type
arb
report
vari
lm
eg
boriskin
et
al
brancato
et
al
brook
et
al
shi
et
al
dose
exhibit
antisarscov
activ
may
like
cytotox
studi
conduct
mouseadapt
flu
model
show
arb
effect
administ
oral
dose
mgkg
leneva
et
al
mgkg
shi
et
al
especi
given
prophylaxi
infect
extrapol
human
dose
would
correspond
g
per
day
evalu
clinic
term
safeti
recent
arb
found
effect
vivo
two
influenza
strain
respons
season
pandem
flu
liu
et
al
reduct
lung
viral
titer
lesion
observ
oral
dose
mgkgday
secret
lung
macrophag
cytokin
modul
indic
inhibitori
effect
arb
virusinduc
inflamm
howev
effect
interferonalpha
observ
line
brook
et
al
contrari
initi
report
glushkov
brook
et
al
report
minor
effect
arb
flu
ainfect
mice
dose
mgkgday
discrep
result
differ
group
might
come
bioavail
issu
due
differ
solvent
use
solubil
arb
dmso
vs
glycerol
ii
anim
model
flu
use
virus
viral
strain
adapt
adapt
mice
iii
dose
administ
anim
howev
overal
antiflu
effect
arb
vivo
seem
appar
mice
rsvinduc
pneumonia
respons
arb
mgkgday
dose
observ
signific
reduct
lung
infecti
titer
compar
untreat
anim
brook
et
al
studi
point
potenti
promis
effect
arb
rsv
vivo
limit
global
studi
address
effect
arb
rsv
invit
moder
call
addit
studi
one
studi
address
antivir
effect
arb
mice
infect
coxsackieviru
mice
develop
interstiti
pneumonia
myocard
receiv
arb
oral
day
dose
mgkg
drug
prolong
surviv
reduc
viral
propag
lung
heart
although
result
complet
pictur
broadspectrum
antivir
activ
arb
must
taken
caution
sinc
sole
studi
viru
conduct
small
number
anim
high
dose
arb
recent
chines
studi
demonstr
antivir
activ
arb
hantaan
viru
envelop
viru
bunyavirida
famili
wei
et
al
caus
often
lethal
hemorrhag
fever
renal
syndrom
hfr
vitro
arb
effici
ad
infect
lm
rang
direct
virucid
effect
note
arb
concentr
lm
vivo
abl
increas
surviv
rate
reduc
histopatholog
chang
viral
load
lethal
model
intracraniallyinfect
suckl
mice
also
serum
level
tnfalpha
modul
sinc
studi
perform
one
research
group
limit
number
anim
reproduc
other
conclud
benefici
effect
arb
hantaviru
infect
howev
arb
efficaci
compar
well
vivo
ribavirin
refer
treatment
diseas
wei
et
al
virus
rhabdovirida
famili
known
induc
neurolog
disord
enceph
recent
report
hemorrhag
fever
grard
et
al
studi
address
effect
arb
viru
famili
conduct
laboratori
vesicular
stomat
viru
vsv
blais
et
al
envelop
rna
viru
mainli
infect
cattl
pig
caus
oral
lesion
anorexia
lethargi
arb
shown
inhibit
vitro
vsv
infect
similar
concentr
rang
alreadi
shown
affect
influenza
rsv
infect
blais
et
al
brook
et
al
lm
shi
et
al
respect
arb
display
optim
antivir
activ
incub
cell
infect
famili
doublestrand
rna
virus
compris
anim
human
pathogen
rotaviru
major
agent
teissier
et
al
gastroenter
children
recent
address
potenti
arb
mammalian
reoviru
strain
blais
et
al
viru
prototyp
member
orthoreoviru
genu
infect
wide
varieti
host
speci
without
caus
signific
patholog
human
spite
reoviru
proven
use
model
studi
viral
pathogenesi
vitro
arb
inhibit
reoviru
infect
lm
rang
interestingli
exert
effect
infecti
subvirion
particl
isvp
intermedi
reoviru
infect
chandran
et
al
could
also
directli
infect
cell
via
differ
entri
mechan
reoviru
martinez
et
al
point
molecular
mechan
action
arb
detail
section
alphaviru
envelop
singlestrand
rna
viru
togavirida
famili
loos
relat
flavivirida
see
hcv
respons
recent
outbreak
rheumatolog
diseas
neurolog
complic
describ
togeth
meningoenceph
arb
demonstr
potent
vitro
activ
chikv
infect
delogu
et
al
arb
show
virucid
activ
contrari
data
respiratori
virus
shi
et
al
zhong
et
al
display
highest
effici
preincub
cell
h
infect
lm
studi
main
metabolit
sulfinyland
sulfonylarb
assay
exhibit
weak
antivir
activ
lm
arb
activ
improv
hpreincub
cell
perform
suggest
metabolit
degrad
product
respons
arb
antivir
action
taken
togeth
result
suggest
interfer
parent
molecul
arb
earli
step
viral
life
cycl
cell
bind
entri
arb
deriv
demonstr
vitro
effici
hepat
b
viru
hbv
envelop
dna
viru
hepadnavirida
famili
zhao
et
al
arb
prevent
hbv
dna
replic
lm
reduc
product
virion
surfac
antigen
hbsag
lm
howev
cytotox
concentr
lm
suggest
inhibitori
concentr
like
cytotox
work
discuss
section
structureact
relationship
sar
section
show
arb
exert
vitro
antivir
activ
hepat
c
viru
hcv
review
boriskin
et
al
member
flavivirida
famili
envelop
virus
specif
arb
effici
incub
cell
infect
left
infect
et
al
alreadi
shown
virus
arb
also
display
virucid
activ
haid
et
al
et
al
lm
rang
arb
inhibit
hcv
entri
fusion
vitro
cellulo
studi
blais
et
al
haid
et
al
teissier
et
al
replic
longer
time
cell
treatment
boriskin
et
al
sellitto
et
al
howev
previous
report
case
influenza
infect
vivo
brook
et
al
arb
found
induc
interferon
antivir
respons
vitro
hcv
boriskin
et
al
studi
arb
molecular
mechan
action
propos
see
section
sever
studi
aim
gain
better
understand
structur
featur
arb
import
broad
antivir
activ
improv
arb
therapeut
index
identifi
novel
lead
compound
activ
emerg
virus
compound
deriv
chemic
structur
arb
synthes
assay
variou
influenza
b
virus
brancato
et
al
amin
posit
hydroxyl
moieti
posit
found
import
arb
antivir
action
wherea
presenc
absenc
br
posit
littl
effect
see
fig
insert
methyl
group
indol
ring
consider
increas
antivir
potenc
result
compound
molecul
shown
directli
bind
greater
affin
arb
presenc
absenc
group
also
influenc
hbv
hcv
infect
sellitto
et
al
zhao
et
al
specif
introduct
particular
azotebas
heterocycl
group
posit
improv
antihbv
activ
littl
effect
hcv
sellitto
et
al
replac
sphenyl
group
posit
phenylsulfonyl
decreas
cytotox
increas
antihbv
activ
compound
zhao
et
al
remov
group
without
influenc
hcv
sellitto
et
al
group
found
dispens
hcv
thu
appear
differ
substitu
arb
molecul
play
role
antivir
activ
depend
viru
consid
cellular
model
use
test
condit
combin
vitro
cellulo
silico
analys
help
refin
sar
arb
particular
silico
molecular
dock
studi
allow
precis
identif
aminoacid
involv
arb
deriv
interact
nasser
et
al
also
threedimension
quantit
sar
help
design
novel
antihbv
compound
base
upon
skeleton
predict
antivir
potenc
chai
et
al
type
approach
also
conceiv
studi
potenti
interact
arb
hcv
envelop
glycoprotein
clarifi
structur
requir
antivir
activ
sinc
hcv
recent
releas
kong
et
al
arb
broadspectrum
antivir
activ
suggest
molecul
act
common
critic
step
viruscel
interact
evid
indic
arb
directli
exert
virucid
effect
consid
directact
antivir
daa
studi
also
report
effect
arb
one
sever
stage
viral
life
cycl
cell
entri
attach
intern
replic
arb
could
therefor
also
act
hosttarget
agent
hta
follow
section
examin
mechan
arb
could
exert
dual
antivir
activ
recapitul
tabl
arb
indolebas
hydrophob
molecul
suscept
format
supramolecular
arrang
aromat
stack
interact
select
aminoacid
residu
protein
phenylalanin
tyrosin
tryptophan
liquidst
nmr
analysi
show
arb
display
interfaci
properti
intercal
shallow
layer
glycerol
backbon
phospholipid
teissier
et
al
even
conceiv
arb
could
local
becom
concentr
viral
cellular
membran
also
shown
arb
interact
aromat
residu
within
viral
glycoprotein
involv
membran
interact
destabil
necessari
fusion
aka
fusion
protein
leneva
et
al
influenza
hemagglutinin
teissier
et
al
hcv
could
therefor
underli
virucid
daa
effect
arb
interact
viral
lipid
envelop
key
residu
within
structur
protein
virion
requir
cellular
receptorcaptor
recognit
andor
membran
fusion
effect
describ
envelop
influenza
viru
shi
et
al
hantaan
viru
hcv
haid
et
al
et
al
nonenvelop
virus
coxsacki
viru
consist
arb
dual
physicochem
properti
arb
could
also
local
impair
viral
attach
cell
plasma
membran
stabil
membran
andor
mask
key
residu
viral
protein
involv
receptor
recognit
sort
daa
hta
effect
would
consequ
viral
entri
shown
fluoresc
spectroscopi
surfac
plasmon
reson
analys
arb
affin
lipid
membran
even
pronounc
acid
ph
optim
ph
fusion
step
sever
envelop
virus
influenza
virus
hcv
particular
fig
haid
et
al
et
al
teissier
et
al
teissier
et
al
interact
phospholipid
may
perturb
membran
fluiditi
therebi
render
lipid
bilay
less
prone
fusion
inhibit
viral
entri
membran
fusion
occur
lm
rang
agreement
arb
affin
membran
concentr
rang
achiev
healthi
volunt
sun
et
al
mechanist
dual
bind
capac
arb
lipid
protein
might
also
underli
alter
proteinprotein
andor
proteinlipid
interact
stage
viral
life
cycl
replic
assembl
bud
number
virus
particular
flavivirida
famili
replic
occur
subcellular
compart
call
membran
web
heaton
randal
moradpour
et
al
membran
web
eman
endoplasm
reticulum
induc
viral
protein
hcv
gouttenoir
et
al
romerobrey
et
al
sinc
web
creat
maintain
interact
viral
cellular
protein
lipid
plausibl
arb
could
impair
viral
replic
abil
bind
protein
lipid
concern
viral
assembl
bud
intracellular
membran
oblig
partner
nucleocapsid
packag
envelop
virus
secret
newli
assembl
viral
particl
case
hcv
viral
assembl
concomit
assembl
lipoprotein
give
rise
lipoviro
particl
bartenschlag
et
al
arb
could
therefor
interfer
process
physicochem
dual
interact
lipid
protein
recent
provid
molecular
detail
arb
inhibit
viru
entri
target
cell
studi
base
livecel
confoc
imag
use
hcv
model
envelop
viru
blais
et
al
fig
first
arb
found
drastic
imped
virion
attach
cell
plasma
membran
arb
subsequ
impair
releas
clathrinco
pit
ccp
plasma
membran
result
slow
clathrinco
vesicl
ccv
intracellular
traffick
net
result
intracellular
accumul
ccv
contain
trap
virion
arb
also
shown
affect
clathrinmedi
endocytosi
cme
imped
membran
scission
therebi
ccp
format
lastli
arb
inhibit
fusion
endocyt
vesicl
endosom
hinder
viral
intracellular
traffick
virion
properli
deliv
endosom
compart
fusion
occur
andor
recruit
virioncontain
vesicl
result
fusion
greatli
impair
virion
traffick
endolysosom
compart
degrad
overal
data
suggest
arb
dual
interact
lipid
protein
may
alter
sever
aspect
intracellular
traffick
matur
endosom
compart
arb
may
imped
recruit
andor
disassembl
machineri
requir
proper
endosom
traffick
viral
entri
thu
arb
inhibit
key
actor
intracellular
traffick
may
like
explan
broadspectrum
antivir
activ
tabl
fig
suggest
arb
act
hta
studi
arb
exert
maxim
antivir
effect
use
infect
indic
activ
earli
stage
viral
infect
andor
requir
arb
impregn
cell
current
state
literatur
arb
shown
activ
virus
enter
cell
rout
requir
least
one
featur
acidif
actin
reoviru
vsv
hcv
hijack
cme
respect
boulant
et
al
johannsdottir
et
al
meerten
et
al
hbv
also
like
enter
via
pathway
yan
et
al
chikv
entri
mainli
achiev
via
cme
leung
et
al
altern
clathrinindepend
pathway
describ
depend
upon
ph
actin
cytoskeleton
integr
bernard
et
al
virus
influenza
hantaan
enter
clathrindepend
independ
endocytot
pathway
acidif
common
review
mercer
heleniu
lozach
et
al
rsv
entri
achiev
macropinocytosi
shown
hcv
intracellular
traffick
virion
krzyzaniak
et
al
picornavirida
famili
group
b
coxsackievirus
entri
epitheli
cell
occur
via
complex
process
combin
caveolindepend
endocytosi
featur
macropinocytosi
depend
upon
coyn
et
al
also
famili
polioviru
reli
actinand
tyrosin
kinasedepend
endocyt
pathway
invad
target
cell
brandenburg
et
al
rhinoviru
entri
phdepend
like
achiev
macropinocytosi
khan
et
al
concern
sarscov
entri
consensu
featur
depend
acidif
intern
cell
compart
inou
et
al
wang
et
al
apart
lipid
membran
therefor
conceiv
arb
act
sever
cellular
target
common
life
cycl
variou
virus
studi
directli
address
arb
hta
interact
protein
intracellular
traffick
avail
present
work
hcv
element
clathrin
coat
could
potenti
target
blais
et
al
also
conceiv
element
cytoskeleton
could
target
inde
molecul
base
arylthioindol
skeleton
fig
close
relat
arb
chemic
inhibitor
tubulin
polymer
therebi
potent
anticanc
agent
la
regina
et
al
arb
report
inhibit
influenzaand
hcvmediat
membran
fusion
leneva
et
al
teissier
et
al
vitro
studi
show
arb
increas
stabil
influenza
viru
hemagglutinin
ha
hinder
low
ph
structur
reorgan
necessari
ha
adopt
fusiogen
conform
thu
block
infect
viral
fusion
step
leneva
et
al
see
also
section
concern
hcv
fusion
inhibit
dosedepend
depend
hcv
genotyp
lipid
composit
target
membran
liposom
predominantli
prevail
low
ph
boriskin
et
al
haid
et
al
et
al
teissier
et
al
arb
found
directli
interact
peptid
hcv
glycoprotein
teissier
et
al
within
pocket
influenza
subunit
hemagglutinin
nasser
et
al
therebi
exert
effect
daa
interestingli
peptid
pocket
contain
aromat
residu
tyrosin
tryptophan
could
engag
aromat
stack
interact
arb
molecul
describ
arb
may
therefor
inhibit
fusion
impair
conform
chang
viral
fusion
protein
initi
fusion
daa
activ
increas
membran
rigid
render
membran
refractori
destabil
requir
fusion
hta
activ
arb
shown
inhibit
hcv
replic
replicon
system
ie
cell
cultur
context
viru
replic
without
product
infecti
viral
particl
boriskin
et
al
sellitto
et
al
progress
declin
viral
protein
rna
express
observ
arbtreat
cell
cell
could
cure
replic
viral
rna
week
arb
treatment
boriskin
et
al
sinc
hcv
modul
lipid
metabol
bassendin
et
al
creat
lipidrich
intern
membran
environ
favor
viru
replic
ie
membran
web
arb
could
therefor
impregn
membran
imped
format
mainten
membran
web
turn
viral
replic
chikv
replic
take
place
host
cell
cytoplasm
associ
cytoplasm
membran
alter
solignat
et
al
replic
complex
attach
membran
modifi
endosom
lysosom
form
organel
characterist
alphaviru
replic
call
type
cytopath
vacuol
vacuol
consist
vesicl
lm
diamet
harbor
numer
spherul
grimley
et
al
posit
lysosom
marker
kujala
et
al
vacuol
produc
viral
rna
cell
death
alreadi
describ
hcv
lipid
bilay
therefor
essenti
chikv
replic
thu
plausibl
arb
may
also
imped
format
stabil
vacuol
therebi
perturb
chikv
replic
absenc
studi
aim
address
potenti
interact
arb
cellular
protein
involv
viral
replic
one
exclud
interact
might
occur
alreadi
suggest
viral
entrymatur
stage
date
report
made
concern
effect
arb
viral
assembl
howev
investig
still
need
address
question
directli
concern
viral
bud
recent
studi
support
notion
arb
could
inhibit
influenza
viru
egress
viral
rna
accumul
cell
later
stage
infect
brook
et
al
arb
impregn
cellular
membran
andor
target
protein
involv
intracellular
traffick
relat
viral
morphogenesisbud
could
underli
observ
spite
usag
russia
china
sever
year
flu
arb
seem
gener
high
degre
viral
resist
epidem
strain
influenza
isol
russia
reveal
resist
oseltamivir
andor
rimantadin
sensit
arb
pandem
swine
influenza
found
larg
resist
rimantadin
retain
sensit
oseltamivir
tamiflu
arb
iatsyshina
et
al
influenza
b
virus
found
caus
vast
epidem
russia
test
strain
sensit
oseltamivir
zanamivir
relenza
arbidol
resist
rimantadin
lvov
et
al
howev
resist
arb
variou
strain
influenza
virus
report
particular
popul
influenza
b
studi
aim
understand
antiinfluenza
mechan
action
arb
leneva
colleagu
isol
seven
viral
mutant
influenza
weybridg
strain
refractori
arb
dose
lm
leneva
et
al
mutant
exhibit
singl
mutat
subunit
influenza
hemagglutinin
subunit
involv
membran
fusion
translat
function
increas
ph
requir
induc
conform
chang
arb
found
directli
interact
therebi
increas
stabil
ph
imped
fusion
endosom
viru
infect
use
eleg
proteom
approach
interact
investig
nasser
cowork
found
confin
one
peptid
encompass
residu
region
contain
arb
alreadi
identifi
mutat
resist
leneva
et
al
nasser
et
al
taken
togeth
data
reveal
resist
influenza
virus
arb
mainli
aris
mutat
fusion
protein
consist
arb
antivir
activ
relat
membran
fusion
address
arb
antivir
mechan
action
chikv
delogu
cowork
isol
mutant
viru
adapt
arb
lm
delogu
et
al
viru
character
singl
mutat
viral
envelop
glycoprotein
region
like
involv
cellsurfac
receptor
recognit
mayb
indirectli
membran
fusion
clearli
addit
studi
arb
resist
context
viral
infect
warrant
conclus
broadspectrum
activ
arb
may
aris
dualiti
function
capac
interact
membran
viral
andor
cellular
protein
arb
therefor
featur
daa
hta
interact
would
imped
cellular
process
pathway
hijack
sever
virus
infect
host
cell
regard
hcv
shown
arb
inhibit
step
hcv
entri
attach
intern
final
step
membran
fusion
arb
also
inhibit
hcv
replic
may
aris
via
alter
intracellular
membraneprotein
structur
essenti
intracellular
traffick
eg
clathrin
coat
compon
element
cytoskeleton
viru
replic
eg
membran
web
could
hinder
membran
rearrang
necessari
viral
bud
step
broadspectrum
activ
cellular
mechan
affect
arb
summar
fig
effect
arb
could
display
antivir
activ
virus
hijack
similar
cellular
pathway
overlap
life
cycl
particular
endocytosi
use
sever
virus
viral
famili
includ
human
immunodefici
viru
von
kleist
et
al
adenovirida
arenavirida
coronavirida
togavirida
achiev
product
infect
tabl
moreov
positivestrand
rna
virus
eukaryot
known
reorgan
intracellular
membran
creat
specif
viru
replic
organel
reason
effort
pursu
order
determin
potenti
inhibitori
effect
arb
larg
class
virus
better
understand
molecular
mechan
action
would
also
contribut
refin
condit
could
given
longterm
regimen
chronic
infect
eg
hepat
b
c
inde
current
data
toxic
issu
insuffici
evalu
safeti
arb
chronic
administr
nevertheless
studi
point
good
toler
molecul
present
state
knowledg
arb
could
therefor
constitut
costeffect
pharmacolog
approach
afford
emerg
countri
urgent
need
effect
antivir
therapi
